Stock Analiz

Protagonist Therapeutics, Inc (PTGX) stock forecast and price target

Price $130.95 · data as of November 13, 2026

12-month price target

Average target$182.36
Upside / downside+39.3%
Analysts14
ConsensusStrong buy
Low $151.00Average $182.36High $225.00

Gold marker: average target · white marker: today’s price ($130.95)

Analyst ratings

Strong buy 3Buy 11Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$5.09+348.1%$565M
Next fiscal year
ends December 31, 2027
$0.39−92.3%$236M
Next quarter
ends December 31, 2026
$-0.22+68.7%$48M
Quarter after
ends March 31, 2027
$0.36+629.0%$58M

Consensus of the analysts covering Protagonist Therapeutics, updated daily. In the last 30 days 3 estimates were raised and 3 lowered.

Our model vs. Wall Street

Analysts see 39.3% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Protagonist Therapeutics’s intrinsic value about 98% below today’s market value, and it scores 1.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Protagonist Therapeutics stock price target?

The average 12-month target from 14 analysts is $182.36, 39.3% above the current price of $130.95 Targets range from $151.00 to $225.00.

Is Protagonist Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (3 strong buy, 11 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Protagonist Therapeutics expected to earn?

Analysts expect EPS of $5.09 for the fiscal year ending December 31, 2026 and $0.39 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.